Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis

被引:9
|
作者
Kelly, Bridget N. [1 ]
Webster, Alexandra J. [1 ]
Lamb, Leslie [2 ]
Spivey, Tara [1 ]
Korotkin, Jenna E. [1 ]
Henriquez, Anthony [1 ]
Gadd, Michele A. [1 ]
Hughes, Kevin S. [1 ]
Lehman, Constance R. [2 ]
Smith, Barbara L. [1 ]
Specht, Michelle C. [1 ]
机构
[1] Massachusetts Gen Hosp, Div Surg Oncol, Yawkey 7,55 Fruit St, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Radiol, Boston, MA 02114 USA
关键词
Breast conserving surgery; Magnetic seed localization; Wireless localization; Lumpectomy; Preoperative; identification (RFID) seeds; nonradioactive radar localization (SAVI; ONCOLOGY CONSENSUS GUIDELINE; CONSERVING SURGERY; AMERICAN SOCIETY; LOCALIZATION; IRRADIATION; MARGINS; LESIONS; SYSTEM;
D O I
10.1016/j.clbc.2022.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Magnetic seed is an alternative to wires for localization of nonpalpable breast lesions that uses a wireless detector probe to guide the surgeon to an implanted magnetic seed. Operative time, specimen volume, postoperative opioid administration, and re-excision rate were compared between the 2 cohorts. We found magnetic seeds to be a feasible alternative to wires with regard to surgical outcomes. Introduction: Magnetic seeds have emerged as an alternative to wires for localization of nonpalpable breast lesions. The purpose of this study was to evaluate the utility of magnetic seeds compared to wires for preoperative localization. Materials and Methods: A retrospective cohort analysis of magnetic seed localization (MSL) and wire localization (WL) excisional biopsies and lumpectomies performed at a single institution was conducted. Indication, age, BMI, number of markers, procedure type, operative time, and postoperative opioid administration were reviewed. Impact of localization method on operative time, specimen volume, postoperative opioid administration, and re-excision rate were assessed. Results: A total of 608 MSL procedures in 601 patients were compared to 628 WL procedures in 620 patients. MSL excisional biopsies were significantly longer (37.0 minutes) than WL excisional biopsies (31.9 minutes, P < .001), but in lumpectomies without axillar y surger y, MSL procedures (42.3 minutes) were significantly shorter than WL procedures (46.9 minutes, P = .017). Significantly less tissue was excised during MSL lumpectomies (68.5 cm 3 ) and excisional biopsies (32.3 cm 3 ) than WL lumpectomies (78.1 cm 3 , P = .039) and excisional biopsies (38.7 cm 3 , P = .018). Postoperative opioid administration was similar for MSL and WL procedures ( P = .076). Re-excision rates for MSL lumpectomies were significantly higher for ductal carcinoma in situ (35.3% MSL vs. 18.5% WL, P = .013), but were similar for invasive carcinoma (14.4% MSL vs. 17.7% WL, P = .290). Logistic regression analysis showed no association between localization method and re-excision (OR 1.007, 95% CI 0.681-1.488; P = .973). Conclusion: MSL is a feasible alternative to WL for excision of nonpalpable breast lesions with regard to surgical outcomes.
引用
收藏
页码:E700 / E707
页数:8
相关论文
共 50 条
  • [1] Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
    Dai, Wei Fang
    Beca, Jaclyn M.
    Nagamuthu, Chenthila
    Liu, Ning
    de Oliveira, Claire
    Earle, Craig C.
    Trudeau, Maureen
    Chan, Kelvin K. W.
    JAMA ONCOLOGY, 2022, 8 (04) : 597 - 606
  • [2] Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil
    Botelho, Carlos Henrique
    Estevez-Diz, Maria Del Pilar
    Campolina, Alessandro Goncalves
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 63 - 72
  • [3] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] Cost-Effectiveness Analysis of Advanced Radiotherapy Techniques for Breast Cancer Patients
    Xie, Y.
    Zhang, R.
    Guo, B.
    MEDICAL PHYSICS, 2020, 47 (06) : E733 - E733
  • [5] Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Xiaolu
    Qin, Qun
    Zhu, Hong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for early breast cancer
    Wardley, Andrew M.
    Cameron, David A.
    Bell, Richard
    Erny, Samuel
    Cohen, Carole
    Geary, Una
    Walzer, Stefan
    Gyldmark, Marlene
    ANNALS OF ONCOLOGY, 2006, 17 : 95 - 96
  • [7] Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium
    Neyt, Mattias
    Huybrechts, Michel
    Hulstaert, Frank
    Vrijens, France
    Ramaekers, Dirk
    HEALTH POLICY, 2008, 87 (02) : 146 - 159
  • [8] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
    Guan, X.
    Li, H-C.
    Chen, Q-J.
    Hua, B.
    Li, J-J.
    Ma, F.
    Wang, Y-S.
    Xu, H.
    Liu, C.
    Yang, Q.
    Ma, A-X.
    ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
  • [9] Cost-effectiveness analysis of trastuzumab therapy in patients with early hill positive breast cancer in Brazil
    Correa, M.
    Perdicaris, M.
    Vernaglia, P. R. W.
    Da Cunha, F. M.
    Saggia, M. G.
    Santos, E. A.
    Nasciben, V
    VALUE IN HEALTH, 2007, 10 (06) : A327 - A327
  • [10] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER
    Mudumba, R.
    Chan, H.
    Cheng, Y. Y.
    Wang, C. C.
    Correia, L.
    Ballreich, J.
    Levy, J.
    VALUE IN HEALTH, 2022, 25 (12) : S95 - S95